Skip to content
2000
Volume 8, Issue 2
  • ISSN: 1874-4710
  • E-ISSN: 1874-4729

Abstract

Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA-peptides requires 177Lu with high specific activity (SA) and values >740 GBq 177Lu per mg Lu to maximise the atom% of 177Lu over total Lu. Vendors provide SA values which are based on activity and mass of the target, whereas due to "burn-up" of target, these SA values are not accurate. For a radiochemist the SA of 177Lu is of interest prior to radiolabeling. An alternative method to determine SA was developed by HPLC, which includes a metal titration of a known amount of DOTA-peptide with a known amount of activity (177Lu), and a unknown amount of metal (177+natLu). Based on an HPLC separation of radiometal-DOTA-peptide and DOTA-peptide, and the concordant ratio of these components the metal content (177+natLu) can be calculated, and eventually the SA of 177Lu can be accurately determined. These experimentally determined SA values exceeded the estimated values provided by vendors by 27±16%, (range 6-73 %). The deviation of SA values for samples from the same Lu batch was <2% (n≥10). In conclusion: the SA of 177Lu is apparently often higher as stated by vendors in comparison to the experimentally determined actual values. For this reason, the SA of 177Lu-DOTA-TATE and other Lu-DOTA-peptides could be increased accordingly.

Loading

Article metrics loading...

/content/journals/crp/10.2174/1874471008666150312162340
2015-08-01
2025-05-28
Loading full text...

Full text loading...

/content/journals/crp/10.2174/1874471008666150312162340
Loading

  • Article Type:
    Research Article
Keyword(s): 177Lu-DOTA-TATE; DOTA-peptides; HPLC; Lutetium-177; specific activity; titration
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test